Anika Therapeutics, Inc. reported fiscal year 2026 results: revenue $114 to $122.5 million. Guidance reaffirmed.
“Fiscal 2026 Guidance Anika is maintaining the previously provided 2026 guidance: Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year OEM Channel, $61 to $64.5 million, flat to modestly lower year over year Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.”
Earnings Releases
Anika Therapeutics, Inc. reported first quarter 2026 results: revenue $29.6 million, net income $5.1 million loss, EPS ($0.37) per diluted share.
“First Quarter 2026 Continuing Operations Financial Summary Revenue $29.6 million, up 13% year over year Commercial Channel revenue $12.6 million, up 12% OEM Channel revenue $17.0 million, up 14% Gross margin 64.2% Operating expenses $24.5 million, including $4.9 million of one-time severance expenses GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share”
Glenn R. Larsen resigned as Class II member of the Board at Anika Therapeutics, Inc..
“On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").”
William R. Jellison resigned as Class I member of the Board of Directors at Anika Therapeutics, Inc..
“On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").”
Anne Nunes departed as Chief Operations Officer at Anika Therapeutics, Inc..
“On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025.”
Joseph Capper was appointed as Director at Anika Therapeutics, Inc..
“the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.”
William Jellison was appointed as Director at Anika Therapeutics, Inc..
“the Board of the Company increased its size from eight to ten directors and appointed (i) Mr. Jellison to the Board as a Class I director, with a term expiring at 2024 Annual Meeting and (ii) Mr. Capper to the Board as a Class II director, with a term expiring at the Company’s 2025 annual meeting of stockholders.”
Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..
“who tendered his resignation on May 2, 2024”
Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..
“announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024”
Earnings Releases
Anika Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $40.5 million, net income $(4.5) million, or ($0.31) per share, EPS $0.09 per diluted share. Guidance reaffirmed.
“orthopedics, today reported financial results for its first quarter ended March 31, 2024. First Quarter 2024 Financial Summary Revenue in the first quarter of 2024 was $40.5 million, up 7% compared to $37.9 million in the first quarter of 2023. OA Pain Management revenue of $24.3 million, up 7% Joint Preservation and Restoration revenue of $13.8 million, up”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.